Company intelligence / Profile preview
Dogwood Therapeutics, Inc.
Atlanta, Georgia, United Statesdwtx.com ↗
- Ownership
- Public · DWTX
- Employees
- ~12
- Development stage
- Phase 2
01
Overview
Currently conducting Phase 2b trial for Halneuron in CINP with interim data expected in Q4 2025. Previous Phase 2 clinical trial demonstrated statistically significant reduction in cancer-related pain with acceptable safety profile. IMC-2 has shown successful reduction of fatigue associated with Long COVID in clinical trials.
- Therapeutic areas
- OncologyRheumatologyNeurologyInfectious Diseases
- Modalities
- Small moleculesCombination therapiesSodium channel blockers
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Exploring partnerships for IMC-1 Phase 3 development
04
Financials
- Market cap
- $39.8M
- Total revenue
- $0
- Enterprise value
- $-4.9T
Beyond the preview
Go deeper on Dogwood Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dogwood Therapeutics, Inc..